Aeglea BioTherapeutics, Inc. AGLE NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

Aeglea BioTherapeutics, Inc. (AGLE) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 3 Buy, 5 Hold.

AGLE Analyst Ratings

Hold

Ratings

3 Buy

5 Hold

Based on 8 analysts giving stock ratings to Aeglea BioTherapeutics, Inc. in the past 3 months

Rating breakdown

Buy

3 38%

Hold

5 63%

38%

Buy

3 analysts

63%

Hold

5 analysts

Sell

0 analysts

People Also View

EWTX

Edgewise Therapeutics, Inc.

Design Therapeutics, Inc.

$12.64

+2.35%

CTMX

CytomX Therapeutics, Inc.

Catalyst Biosciences, Inc.

$19.52

+8.50%

ASMB

Assembly Biosciences, Inc.

$29.44

+0.68%

BNTC

Benitec Biopharma Inc.

$13.25

+10.42%

Aeglea BioTherapeutics, Inc. AGLE NASDAQ

AGLE Analyst Ratings

People Also View

Get Undervalued Stock Alerts